Latest & greatest articles for testosterone

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on testosterone or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on testosterone and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for testosterone

121. The Effect of Testosterone on Metabolic Syndrome and Type 2 Diabetes

The Effect of Testosterone on Metabolic Syndrome and Type 2 Diabetes "The Effect of Testosterone on Metabolic Syndrome and Type 2 Diabetes" by Alison Quammen < > > > > > Title Author Date of Graduation 8-14-2010 Degree Type Capstone Project Degree Name Master of Science in Physician Assistant Studies First Advisor Mary Von PA-C Second Advisor Annjanette Sommers MS, PAC Third Advisor Rob Rosenow PharmD, OD Rights . Abstract Background: Metabolic syndrome (MetS) and diabetes type 2 (DM2 (...) a link between hypogonadism and metabolic syndrome and the next step is to evaluate if raising a man’s testosterone levels back to physiologic norms has any benefit in the treatment of metabolic syndrome or DM2. Methods: A comprehensive review of the literature was performed using the data bases: CINAHL, ovid - Medline, EBMR Multifile, Web of Science, PubMed and Google scholar. This produced a number of studies and the following exclusion criteria were applied to limit the search. Exclusion criteria

2010 Pacific University EBM Capstone Project

122. Axiron (testosterone) topical solution

Axiron (testosterone) topical solution Drug Approval Package: Axiron (testosterone) NDA #022504 Drug Approval Package U.S. Food & Drug Administration Search FDA Drug Approval Package - Axiron (testosterone) topical solution Company: Acrux Pharma Pty Ltd. Application No.: 022504 Approval Date: 11/23/2010 Persons with disabilities having problems accessing the PDF files below may call (301) 796-3634 for assistance. (PDF) (PDF) (PDF) (PDF) (PDF) (PDF) (PDF) (PDF) (PDF) (PDF) (PDF) (PDF) (PDF) (PDF

2010 FDA - Drug Approval Package

123. Fortesta (testosterone) Gel for topical use

Fortesta (testosterone) Gel for topical use Drug Approval Package: Fortesta (testosterone) NDA #021463 Drug Approval Package U.S. Food & Drug Administration Search FDA Drug Approval Package - Fortesta (testosterone) Gel for topical use, 10 mg of testosterone per pump actuation Company: Endo Pharmaceuticals, Inc. Application No.: 021463 Approval Date: 12/29/2010 Persons with disabilities having problems accessing the PDF files below may call (301) 796-3634 for assistance. (PDF) (PDF) (PDF) (PDF

2010 FDA - Drug Approval Package

124. Adverse effects of testosterone therapy in adult men: a systematic review and meta-analysis Full Text available with Trip Pro

Adverse effects of testosterone therapy in adult men: a systematic review and meta-analysis Adverse effects of testosterone therapy in adult men: a systematic review and meta-analysis Adverse effects of testosterone therapy in adult men: a systematic review and meta-analysis Fernandez-Balsells MM, Murad MH, Lane M, Lampropulos JF, Albuquerque F, Mullan RJ, Agrwal N, Elamin MB, Gallegos-Orozco JF, Wang AT, Erwin PJ, Bhasin S, Montori VM CRD summary This review concluded that although haemoglobin (...) and haematocrit increased and high density lipoprotein cholesterol decreased in men who received testosterone therapy, the clinical significance of these findings was unclear and the evidence base was deficient. The review had some limitations, but the authors were appropriately cautious regarding the reliability of the results given the limitations of the original studies. Authors' objectives To determine the adverse events associated with testosterone therapy in adult men. Searching MEDLINE, EMBASE

2010 DARE.

125. Adverse events associated with testosterone administration. Full Text available with Trip Pro

Adverse events associated with testosterone administration. Testosterone supplementation has been shown to increase muscle mass and strength in healthy older men. The safety and efficacy of testosterone treatment in older men who have limitations in mobility have not been studied.Community-dwelling men, 65 years of age or older, with limitations in mobility and a total serum testosterone level of 100 to 350 ng per deciliter (3.5 to 12.1 nmol per liter) or a free serum testosterone level of less (...) than 50 pg per milliliter (173 pmol per liter) were randomly assigned to receive placebo gel or testosterone gel, to be applied daily for 6 months. Adverse events were categorized with the use of the Medical Dictionary for Regulatory Activities classification. The data and safety monitoring board recommended that the trial be discontinued early because there was a significantly higher rate of adverse cardiovascular events in the testosterone group than in the placebo group.A total of 209 men (mean

2010 NEJM Controlled trial quality: uncertain

126. Effects of testosterone replacement in middle-aged men with dysthymia: a randomized, placebo-controlled clinical trial (Abstract)

Effects of testosterone replacement in middle-aged men with dysthymia: a randomized, placebo-controlled clinical trial Mid-life onset male dysthymic disorder (DD) seems to be a distinct clinical condition with limited therapeutic options. Testosterone replacement is mood-enhancing and has been proposed as an antidepressant therapy, though this strategy has received limited systematic study. We therefore conducted a six-week double-blind placebo-controlled clinical trial in 23 men with DD (...) and with low or low-normal testosterone (T) level (i.e, screening total serum testosterone <350 ng/dL). Enrolled men were randomized to receive intramuscular injections of 200 mg of testosterone cypionate or placebo every 10 days. The primary outcome measures were the Clinical Global Impression (CGI) improvement score and the 21-item Hamilton Depression Rating Scale (HDRS) score.Twenty-three patients were randomized. The mean (SD) age of the enrolled patients was 50.6 (7.0) years and that of total

2009 EvidenceUpdates Controlled trial quality: predicted high

127. Testosterone and depression: systematic review and meta-analysis

Testosterone and depression: systematic review and meta-analysis Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.

2009 DARE.

128. Testosterone therapy in hypogonadal men and potential prostate cancer risk: a systematic review

Testosterone therapy in hypogonadal men and potential prostate cancer risk: a systematic review Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.

2009 DARE.

129. Testosterone for low sexual desire in surgically postmenopausal women

Testosterone for low sexual desire in surgically postmenopausal women Testosterone for low sexual desire in surgically postmenopausal women Testosterone for low sexual desire in surgically postmenopausal women Record Status This is a bibliographic record of a published health technology assessment. No evaluation of the quality of this assessment has been made for the HTA database. Report may be purchased from . Citation Testosterone for low sexual desire in surgically postmenopausal women (...) . Lansdale: HAYES, Inc.. 2009 Authors' objectives Administration of exogenous testosterone has been investigated as a treatment for low sexual desire in women. Endogenous androgens, produced in women by the ovaries, adrenal glands, and peripheral tissue, are thought to play a role in the regulation of sexual desire. In women in whom both ovaries are removed (bilateral oophorectomy), testosterone levels drop substantially and sexual desire may be reduced. Although the precise relationship between

2009 Health Technology Assessment (HTA) Database.

130. Testosterone for low sexual desire in premenopausal women

Testosterone for low sexual desire in premenopausal women Testosterone for low sexual desire in premenopausal women Testosterone for low sexual desire in premenopausal women Record Status This is a bibliographic record of a published health technology assessment. No evaluation of the quality of this assessment has been made for the HTA database. Report may be purchased from . Citation Testosterone for low sexual desire in premenopausal women . Lansdale: HAYES, Inc.. 2009 Authors' objectives (...) Administration of exogenous testosterone has been investigated as a treatment for low sexual desire in women. Endogenous androgens, produced in women by the ovaries, adrenal glands, and in peripheral tissue, are thought to play a role in the regulation of sexual desire. Although the precise relationship between testosterone levels and sexual desire in women is not clear, the goal of testosterone therapy is to increase sexual desire. Project page URL Indexing Status Subject indexing assigned by CRD MeSH

2009 Health Technology Assessment (HTA) Database.

131. Short-term testosterone augmentation in male schizophrenics: a randomized, double-blind, placebo-controlled trial Full Text available with Trip Pro

Short-term testosterone augmentation in male schizophrenics: a randomized, double-blind, placebo-controlled trial Although there are few studies on the treatment of schizophrenia with testosterone, several indirect findings have suggested testosterone as a possible treatment modality for schizophrenia. To explore the therapeutic effect of testosterone augmentation of antipsychotic medication on symptoms in male patients with schizophrenia, the authors performed a placebo-controlled, double (...) -blind trial on 30 schizophrenic men, using either 5 g of 1% testosterone gel (Testogel; Besins Iscovesco, Paris, France) or a placebo added to a fixed dosage of antipsychotic medication over a period of 4 weeks with a 2-week washout period. In addition, to get additional information about the involvement of these reproductive hormones after testosterone augmentation, the authors evaluated several hormones such as total testosterone, free testosterone, dehydroepiandrosterone sulfate, estradiol

2008 EvidenceUpdates Controlled trial quality: uncertain

132. Effect of testosterone supplementation on functional mobility, cognition, and other parameters in older men: a randomized controlled trial. Full Text available with Trip Pro

Effect of testosterone supplementation on functional mobility, cognition, and other parameters in older men: a randomized controlled trial. Serum testosterone levels decline significantly with aging. Testosterone supplementation to older men might beneficially affect the aging processes.To investigate the effect of testosterone supplementation on functional mobility, cognitive function, bone mineral density, body composition, plasma lipids, quality of life, and safety parameters in older men (...) with low normal testosterone levels.Double-blind, randomized, placebo-controlled trial of 237 healthy men between the ages of 60 and 80 years with a testosterone level lower than 13.7 nmol/L conducted from January 2004 to April 2005 at a university medical center in the Netherlands.Participants were randomly assigned to receive 80 mg of testosterone undecenoate or a matching placebo twice daily for 6 months.Functional mobility (Stanford Health Assessment Questionnaire, timed get up and go test

2008 JAMA Controlled trial quality: predicted high

133. Testosterone for low libido in postmenopausal women not taking estrogen. Full Text available with Trip Pro

Testosterone for low libido in postmenopausal women not taking estrogen. The efficacy and safety of testosterone treatment for hypoactive sexual desire disorder in postmenopausal women not receiving estrogen therapy are unknown.We conducted a double-blind, placebo-controlled, 52-week trial in which 814 women with hypoactive sexual desire disorder were randomly assigned to receive a patch delivering 150 or 300 microg of testosterone per day or placebo. Efficacy was measured to week 24; safety (...) was evaluated over a period of 52 weeks, with a subgroup of participants followed for an additional year. The primary end point was the change from baseline to week 24 in the 4-week frequency of satisfying sexual episodes.At 24 weeks, the increase in the 4-week frequency of satisfying sexual episodes was significantly greater in the group receiving 300 microg of testosterone per day than in the placebo group (an increase of 2.1 episodes vs. 0.7, P<0.001) but not in the group receiving 150 microg per day

2008 NEJM Controlled trial quality: predicted high

134. Testosterone supplementation did not prevent cognitive decline or increase bone mineral density in older men

Testosterone supplementation did not prevent cognitive decline or increase bone mineral density in older men Testosterone supplementation did not prevent cognitive decline or increase bone mineral density in older men | BMJ Evidence-Based Medicine We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn more about how we use cookies, please see our . Log in using your username and password (...) For personal accounts OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Testosterone supplementation did not prevent cognitive decline or increase bone mineral density in older men Article Text Therapeutics Testosterone supplementation did not prevent

2008 Evidence-Based Medicine

135. Testosterone for schizophrenia. (Abstract)

Testosterone for schizophrenia. Recently, sex hormones such as estrogens and testosterone or its derivatives have been the focus of interest for treatment of persistent symptoms associated with schizophrenia.To review the effects of dehydroepiandrosterone (DHEA)/testosterone as adjunctive therapy to standard antipsychotic drugs.We searched the Cochrane Schizophrenia Group Trials Register (January 2007).We included all clinical randomised trials comparing DHEA/testosterone plus standard

2007 Cochrane

136. Testosterone use in men with sexual dysfunction: a systematic review and meta-analysis of randomized placebo-controlled trials

Testosterone use in men with sexual dysfunction: a systematic review and meta-analysis of randomized placebo-controlled trials Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.

2007 DARE.

137. Testosterone use in men and its effects on bone health: a systematic review and meta-analysis of randomized placebo-controlled trials

Testosterone use in men and its effects on bone health: a systematic review and meta-analysis of randomized placebo-controlled trials Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.

2006 DARE.

138. DHEA in elderly women and DHEA or testosterone in elderly men. Full Text available with Trip Pro

DHEA in elderly women and DHEA or testosterone in elderly men. Dehydroepiandrosterone (DHEA) and testosterone are widely promoted as antiaging supplements, but the long-term benefits, as compared with potential harm, are unknown.We performed a 2-year, placebo-controlled, randomized, double-blind study involving 87 elderly men with low levels of the sulfated form of DHEA and bioavailable testosterone and 57 elderly women with low levels of sulfated DHEA. Among the men, 29 received DHEA, 27 (...) received testosterone, and 31 received placebo. Among the women, 27 received DHEA and 30 received placebo. Outcome measures included physical performance, body composition, bone mineral density (BMD), glucose tolerance, and quality of life.As compared with the change from baseline to 24 months in the placebo group, subjects who received DHEA for 2 years had an increase in plasma levels of sulfated DHEA by a median of 3.4 microg per milliliter (9.2 micromol per liter) in men and by 3.8 microg per

2006 NEJM Controlled trial quality: predicted high

139. Effect of testosterone replacement therapy on prostate tissue in men with late-onset hypogonadism: a randomized controlled trial. Full Text available with Trip Pro

Effect of testosterone replacement therapy on prostate tissue in men with late-onset hypogonadism: a randomized controlled trial. Prostate safety is a primary concern when aging men receive testosterone replacement therapy (TRT), but little information is available regarding the effects of TRT on prostate tissue in men.To determine the effects of TRT on prostate tissue of aging men with low serum testosterone levels.Randomized, double-blind, placebo-controlled trial of 44 men, aged 44 to 78 (...) years, with screening serum testosterone levels lower than 300 ng/dL (<10.4 nmol/L) and related symptoms, conducted at a US community-based research center between February 2003 and November 2004.Participants were randomly assigned to receive 150 mg of testosterone enanthate or matching placebo intramuscularly every 2 weeks for 6 months.The primary outcome measure was the 6-month change in prostate tissue androgen levels (testosterone and dihydrotestosterone). Secondary outcome measures included 6

2006 JAMA Controlled trial quality: predicted high

140. Adverse events associated with testosterone replacement in middle-aged and older men: a meta-analysis of randomized, placebo-controlled trials

Adverse events associated with testosterone replacement in middle-aged and older men: a meta-analysis of randomized, placebo-controlled trials Adverse events associated with testosterone replacement in middle-aged and older men: a meta-analysis of randomized, placebo-controlled trials Adverse events associated with testosterone replacement in middle-aged and older men: a meta-analysis of randomized, placebo-controlled trials Calof OM, Singh AB, Lee ML, Kenny AM, Urban RJ, Tenover JL, Bhasin S (...) CRD summary This review evaluated the risk of adverse events associated with testosterone replacement in older men. The authors concluded that testosterone replacement is associated with a significantly higher risk of prostate events and of a haematocrit of more than 50% relative to placebo. A limited search, unclear review methodology, and the unknown quality of the primary studies limit the reliability of the conclusions. Authors' objectives To determine the risk of adverse events associated

2005 DARE.